The pre-market share price of ARTIVA BIOTHERAPEUTICS fell 30%; after the death of two patients, the company stopped cell therapy and laid off 94% of employees.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.